FDA Releases Revised Guidance to Reduce Risk of Creutzfeldt-Jakob Disease Transmission from Blood and Blood Products

Summary

The US Food and Drug Administration (FDA) has made available a revised guidance document aimed at minimizing the risk of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) transmission from blood and blood products, following the incorporation of recommendations from a draft document.